Clinical trials: Insulin Treated Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
This study will evaluate whether bile acids are able to increase insulin sensitivity and enhance glycemic control in T2DM patients, as well as exploring the mechanisms that enhance glycemic control.
- Trial name
- NCT02033876
- Testing
- Ursodiol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes
This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT01545791)
- Testing
- insulin detemir
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 1,037 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Evaluation of a Treatment and Education Program for Diabetic Patients Who Use Flash Glucose Monitoring
This study is a randomized, controlled, prospective trial with a 6-month follow- up. A newly developed psychoeducational treatment and education programme for diabetic patients on an insulin therapy who use flash glucose…
- Trial name
- FLASH (NCT03175315)
- Testing
- Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- Norbert Hermanns
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin…
- Trial name
- NCT01462266
- Testing
- Sitagliptin, Insulin Glargine, Metformin
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT00982644)
- Testing
- insulin degludec, insulin glargine
- Where
- 187 sites in United States, Austria and 13 more
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Non-Insulin-Dependent
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent.
- Trial name
- OPTIMISE (NCT01694758)
- Where
- 20 sites in Bulgaria, Romania
- Volunteers
- 733 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
The trial is conducted in Asia. The aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in Taiwanese patients with type 2 diabetes failing on OAD with/without once-daily NPH Insulin treatment.
- Trial name
- NCT00521690
- Testing
- insulin detemir
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes
The study is conducted in Asia. The aim of this observational study is to evaluate the weight change from baseline while using Levemir® in subjects with type 2 diabetes mellitus under normal clinical practice conditions in India.
- Trial name
- DIABESITY (NCT00687063)
- Testing
- insulin detemir
- Where
- India
- Volunteers
- 10,008 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 2 Treated With Insulin
Insulin Use and Respiratory Muscle Strength in Type 2 Diabetes
This study compares breathing function, breathing muscle strength, and recovery after a walking test in adults with type 2 diabetes, based on whether they use insulin.
- Trial name
- NCT07377448
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Izmir Bakircay University
Continuous Glucose Monitoring, Type 2 Diabetes
A Study on the Effect of CGM Alone on Glycemic Metrics in Type 2 Diabetes Patients Not Using Insulin, Without Additional Interventions
This study evaluates the effect of using a real-time continuous glucose monitoring (CGM) system on blood sugar control in people with type 2 diabetes who do not use insulin.
- Trial name
- NCT07298850
- Testing
- Continuous glucose monitoring
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Kangbuk Samsung Hospital
Diabetes Mellitus, Type 2
A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
The purpose of the study is to collect information about how NovoMix® 30 works in real world adult population with type 2 diabetes. Participants will get NovoMix® 30 as prescribed by the study doctor.
- Trial name
- B Simple (NCT03862690)
- Testing
- BIAsp 30
- Where
- 2 sites in Algeria
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the…
- Trial name
- IMPROVE™ (NCT00659282)
- Testing
- biphasic insulin aspart
- Where
- 11 sites in Canada, China and 9 more
- Volunteers
- 57,610 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
T2DM (Type 2 Diabetes Mellitus), Continuous Glucose Monitoring
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
To determine whether 3-month versus 6-month professional CGM utilization improves time spent in target range of 70-140mg/dl in patients with poorly controlled T2DM not treated with insulin.
- Trial name
- NCT03067480
- Testing
- iPro2 Professional CGM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- East Tennessee State University
Diabetes, Type 2 Diabetes Mellitus
Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
This trial is conducted in Asia. The aim of the trial is to compare efficacy and safety of thrice daily versus twice daily NovoMix® 30 (Biphasic insulin aspart 30) in subjects with type 2 diabetes inadequately controlled with…
- Trial name
- NCT02582242
- Testing
- biphasic insulin aspart 30
- Where
- 50 sites in Algeria, China and 5 more
- Volunteers
- 437 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Treated With Insulin
Flash CONtinous Glucose Monitoring in TRansition to Outpatient: Libre for Type 2 Diabetes Mellitus (CONTROL-DM)
This is a pilot study of the use of flash glucose monitoring (FGM) to assess glycemic control, behavioural, quality of life benefits and manpower utilization in poorly controlled T2DM patients on insulin in the transitional care…
- Trial name
- CONTROL-DM (NCT04871438)
- Testing
- Flash glucose monitoring
- Where
- Singapore
- Volunteers
- 34 people
- Sponsor
- Woodlands Hospital
Type 2 Diabetes Treated With Insulin, Pregnancy, High Risk
Continuous Glucose Monitor Use in Pregnancy
The purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (T2DM) comparing continuous glucose monitor (CGM) use to the standard of care of multiple daily…
- Trial name
- NCT05317585
- Testing
- Continuous Glucose Monitor, Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Massachusetts, Worcester
Diabetes Mellitus
BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance
The study is designed to compare meal time glucose control associated with BIOD-531, a rapidly absorbed concentrated insulin to that associated with Humalog Mix 75/25 and Humulin R U-500 in patients with diabetes and severe…
- Trial name
- NCT02324309
- Testing
- BIOD-531, Humalog Mix 75/25, Humulin R U-500
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Biodel